Key observations from the NHLBI Asthma Clinical Research Network

Stanley J. Szefler, Vernon M. Chinchilli, Elliot Israel, Loren Clark Denlinger, Robert F. Lemanske, William Calhoun, Stephen P. Peters

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The National Heart, Lung and Blood Institute (NHLBI) Asthma Clinical Research Network (ACRN) recently completed its work after 20 years of collaboration as a multicentre clinical trial network. When formed, its stated mission was to perform multiple controlled clinical trials for treating patients with asthma by dispassionately examining new and existing therapies, and to rapidly communicate its findings to the medical community. The ACRN conducted 15 major clinical trials. In addition, clinical data, manual of operations, protocols and template informed consents from all ACRN trials are available via NHLBI BioLINCC (https://biolincc.nhlbi.nih.gov/studies/). This network contributed major insights into the use of inhaled corticosteroids, short-acting and long-acting β-adrenergic agonists, leukotriene receptor antagonists, and novel agents (tiotropium, colchicine and macrolide antibiotics). They also pioneered studies of the variability in drug response, predictors of treatment response and pharmacogenetics. This review highlights the major research observations from the ACRN that have impacted the current management of asthma.

Original languageEnglish (US)
Pages (from-to)450-455
Number of pages6
JournalThorax
Volume67
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

National Heart, Lung, and Blood Institute (U.S.)
Asthma
Research
Clinical Trials
Leukotriene Antagonists
Adrenergic Agonists
Pharmacogenetics
Macrolides
Controlled Clinical Trials
Colchicine
Informed Consent
Multicenter Studies
Adrenal Cortex Hormones
Anti-Bacterial Agents
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Szefler, S. J., Chinchilli, V. M., Israel, E., Denlinger, L. C., Lemanske, R. F., Calhoun, W., & Peters, S. P. (2012). Key observations from the NHLBI Asthma Clinical Research Network. Thorax, 67(5), 450-455. https://doi.org/10.1136/thoraxjnl-2012-201876
Szefler, Stanley J. ; Chinchilli, Vernon M. ; Israel, Elliot ; Denlinger, Loren Clark ; Lemanske, Robert F. ; Calhoun, William ; Peters, Stephen P. / Key observations from the NHLBI Asthma Clinical Research Network. In: Thorax. 2012 ; Vol. 67, No. 5. pp. 450-455.
@article{1180cada1c354db7bd95e968d55823dd,
title = "Key observations from the NHLBI Asthma Clinical Research Network",
abstract = "The National Heart, Lung and Blood Institute (NHLBI) Asthma Clinical Research Network (ACRN) recently completed its work after 20 years of collaboration as a multicentre clinical trial network. When formed, its stated mission was to perform multiple controlled clinical trials for treating patients with asthma by dispassionately examining new and existing therapies, and to rapidly communicate its findings to the medical community. The ACRN conducted 15 major clinical trials. In addition, clinical data, manual of operations, protocols and template informed consents from all ACRN trials are available via NHLBI BioLINCC (https://biolincc.nhlbi.nih.gov/studies/). This network contributed major insights into the use of inhaled corticosteroids, short-acting and long-acting β-adrenergic agonists, leukotriene receptor antagonists, and novel agents (tiotropium, colchicine and macrolide antibiotics). They also pioneered studies of the variability in drug response, predictors of treatment response and pharmacogenetics. This review highlights the major research observations from the ACRN that have impacted the current management of asthma.",
author = "Szefler, {Stanley J.} and Chinchilli, {Vernon M.} and Elliot Israel and Denlinger, {Loren Clark} and Lemanske, {Robert F.} and William Calhoun and Peters, {Stephen P.}",
year = "2012",
month = "5",
doi = "10.1136/thoraxjnl-2012-201876",
language = "English (US)",
volume = "67",
pages = "450--455",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group",
number = "5",

}

Szefler, SJ, Chinchilli, VM, Israel, E, Denlinger, LC, Lemanske, RF, Calhoun, W & Peters, SP 2012, 'Key observations from the NHLBI Asthma Clinical Research Network', Thorax, vol. 67, no. 5, pp. 450-455. https://doi.org/10.1136/thoraxjnl-2012-201876

Key observations from the NHLBI Asthma Clinical Research Network. / Szefler, Stanley J.; Chinchilli, Vernon M.; Israel, Elliot; Denlinger, Loren Clark; Lemanske, Robert F.; Calhoun, William; Peters, Stephen P.

In: Thorax, Vol. 67, No. 5, 05.2012, p. 450-455.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Key observations from the NHLBI Asthma Clinical Research Network

AU - Szefler, Stanley J.

AU - Chinchilli, Vernon M.

AU - Israel, Elliot

AU - Denlinger, Loren Clark

AU - Lemanske, Robert F.

AU - Calhoun, William

AU - Peters, Stephen P.

PY - 2012/5

Y1 - 2012/5

N2 - The National Heart, Lung and Blood Institute (NHLBI) Asthma Clinical Research Network (ACRN) recently completed its work after 20 years of collaboration as a multicentre clinical trial network. When formed, its stated mission was to perform multiple controlled clinical trials for treating patients with asthma by dispassionately examining new and existing therapies, and to rapidly communicate its findings to the medical community. The ACRN conducted 15 major clinical trials. In addition, clinical data, manual of operations, protocols and template informed consents from all ACRN trials are available via NHLBI BioLINCC (https://biolincc.nhlbi.nih.gov/studies/). This network contributed major insights into the use of inhaled corticosteroids, short-acting and long-acting β-adrenergic agonists, leukotriene receptor antagonists, and novel agents (tiotropium, colchicine and macrolide antibiotics). They also pioneered studies of the variability in drug response, predictors of treatment response and pharmacogenetics. This review highlights the major research observations from the ACRN that have impacted the current management of asthma.

AB - The National Heart, Lung and Blood Institute (NHLBI) Asthma Clinical Research Network (ACRN) recently completed its work after 20 years of collaboration as a multicentre clinical trial network. When formed, its stated mission was to perform multiple controlled clinical trials for treating patients with asthma by dispassionately examining new and existing therapies, and to rapidly communicate its findings to the medical community. The ACRN conducted 15 major clinical trials. In addition, clinical data, manual of operations, protocols and template informed consents from all ACRN trials are available via NHLBI BioLINCC (https://biolincc.nhlbi.nih.gov/studies/). This network contributed major insights into the use of inhaled corticosteroids, short-acting and long-acting β-adrenergic agonists, leukotriene receptor antagonists, and novel agents (tiotropium, colchicine and macrolide antibiotics). They also pioneered studies of the variability in drug response, predictors of treatment response and pharmacogenetics. This review highlights the major research observations from the ACRN that have impacted the current management of asthma.

UR - http://www.scopus.com/inward/record.url?scp=84859833018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859833018&partnerID=8YFLogxK

U2 - 10.1136/thoraxjnl-2012-201876

DO - 10.1136/thoraxjnl-2012-201876

M3 - Review article

C2 - 22514237

AN - SCOPUS:84859833018

VL - 67

SP - 450

EP - 455

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 5

ER -

Szefler SJ, Chinchilli VM, Israel E, Denlinger LC, Lemanske RF, Calhoun W et al. Key observations from the NHLBI Asthma Clinical Research Network. Thorax. 2012 May;67(5):450-455. https://doi.org/10.1136/thoraxjnl-2012-201876